Fig. 9
From: Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer
qPCR analysis of LUVA mast cells exposed to standard of care HGSOC chemotherapy. (A) AREG, (B) CCL2, (C)TGFβ1, (D) VEGFA, (E) TNF, (F) IL-2, (G) CCL7, (H) IL-10, and (I) TGFβ2 mRNA levels in LUVA cells stimulated with 100 μm of carboplatin and 10 nm of paclitaxel for 48h and analyzed via qPCR. Error bars represent standard deviation of ≥ 3 biological replicates. Statistically significant differences determined by Student T-test. NACT, neoadjuvant chemotherapy, HGSOC, high grade serous ovarian cancer, *p < 0.05, ** p < 0.005, as indicated, ns, non-significant